HSBC Holdings
BMRN icon

HSBC Holdings’s BioMarin Pharmaceuticals BMRN Stock Holding History

HSBC Holdings’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-15,100
Closed -$1.22M – 2563
2018
Q1 		$1.22M Buy
+15,100
New +$1.3M ﹤0.01% 1569
2013
Q3 		– Sell
-5,122
Closed -$286K – 1661
2013
Q2 		$286K Buy
+5,122
New +$319K ﹤0.01% 1345

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

HSBC Holdings's BMRN Position: Q2 2026 in Review

HSBC Holdings increased its BioMarin Pharmaceuticals (BMRN) stake by 108% in Q2 2026, buying an estimated $8.73M and bringing the position to 307,543 shares worth $17.6M. The position accounts for 0.01% of the portfolio, ranked #799.

HSBC Holdings first reported a position in BMRN in Q2 2013 and has held it in 53 quarters since. The position peaked at $53.9M in Q3 2023. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • HSBC Holdings held 307,543 shares of BioMarin Pharmaceuticals worth $17.6M as of Q2 2026.
  • HSBC Holdings bought 159,361 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $8.73M.
  • BioMarin Pharmaceuticals made up 0.01% of HSBC Holdings's portfolio in Q2 2026, its #799 holding.
  • HSBC Holdings first reported a position in BioMarin Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
  • HSBC Holdings's BioMarin Pharmaceuticals position peaked at $53.9M in Q3 2023.
  • 565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on HSBC Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.